Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 37 entries
Sorted by: Best Match Show Resources per page
Germline whole exome sequencing and large-scale replication identifies .

Oncotarget

Dicks E, Song H, Ramus SJ, Oudenhove EV, Tyrer JP, Intermaggio MP, Kar S, Harrington P, Bowtell DD, Group AS, Cicek MS, Cunningham JM, Fridley BL, Alsop J, Jimenez-Linan M, Piskorz A, Goranova T, Kent E, Siddiqui N, Paul J, Crawford R, Poblete S, Lele S, Sucheston-Campbell L, Moysich KB, Sieh W, McGuire V, Lester J, Odunsi K, Whittemore AS, Bogdanova N, Dürst M, Hillemanns P, Karlan BY, Gentry-Maharaj A, Menon U, Tischkowitz M, Levine D, Brenton JD, Dörk T, Goode EL, Gayther SA, Pharoah DPP.
PMID: 28881617
Oncotarget. 2017 Mar 03;8(31):50930-50940. doi: 10.18632/oncotarget.15871. eCollection 2017 Aug 01.

We analyzed whole exome sequencing data in germline DNA from 412 high grade serous ovarian cancer (HGSOC) cases from The Cancer Genome Atlas Project and identified 5,517 genes harboring a predicted deleterious germline coding mutation in at least one...

Cite
Dicks E, Song H, Ramus SJ, et al. Germline whole exome sequencing and large-scale replication identifies . Oncotarget. 2017;8(31):50930-50940doi: 10.18632/oncotarget.15871.
Dicks, E., Song, H., Ramus, S. J., Oudenhove, E. V., Tyrer, J. P., Intermaggio, M. P., Kar, S., Harrington, P., Bowtell, D. D., Group, A. S., Cicek, M. S., Cunningham, J. M., Fridley, B. L., Alsop, J., Jimenez-Linan, M., Piskorz, A., Goranova, T., Kent, E., Siddiqui, N., Paul, J., Crawford, R., Poblete, S., Lele, S., Sucheston-Campbell, L., Moysich, K. B., Sieh, W., McGuire, V., Lester, J., Odunsi, K., Whittemore, A. S., Bogdanova, N., Dürst, M., Hillemanns, P., Karlan, B. Y., Gentry-Maharaj, A., Menon, U., Tischkowitz, M., Levine, D., Brenton, J. D., Dörk, T., Goode, E. L., Gayther, S. A., & Pharoah, D. P. P. (2017). Germline whole exome sequencing and large-scale replication identifies . Oncotarget, 8(31), 50930-50940. https://doi.org/10.18632/oncotarget.15871
Dicks, Ed, et al. "Germline whole exome sequencing and large-scale replication identifies ." Oncotarget vol. 8,31 (2017): 50930-50940. doi: https://doi.org/10.18632/oncotarget.15871
Dicks E, Song H, Ramus SJ, Oudenhove EV, Tyrer JP, Intermaggio MP, Kar S, Harrington P, Bowtell DD, Group AS, Cicek MS, Cunningham JM, Fridley BL, Alsop J, Jimenez-Linan M, Piskorz A, Goranova T, Kent E, Siddiqui N, Paul J, Crawford R, Poblete S, Lele S, Sucheston-Campbell L, Moysich KB, Sieh W, McGuire V, Lester J, Odunsi K, Whittemore AS, Bogdanova N, Dürst M, Hillemanns P, Karlan BY, Gentry-Maharaj A, Menon U, Tischkowitz M, Levine D, Brenton JD, Dörk T, Goode EL, Gayther SA, Pharoah DPP. Germline whole exome sequencing and large-scale replication identifies . Oncotarget. 2017 Mar 03;8(31):50930-50940. doi: 10.18632/oncotarget.15871. eCollection 2017 Aug 01. PMID: 28881617; PMCID: PMC5584218.
Copy Download .nbib Format: NLM
Chronic exposure to dioxin-like compounds and thyroid function among New York anglers.

Environmental toxicology and pharmacology

Bloom M, Vena J, Olson J, Moysich K.
PMID: 21783667
Environ Toxicol Pharmacol. 2006 May;21(3):260-7. doi: 10.1016/j.etap.2005.09.001. Epub 2005 Oct 24.

Experimental studies suggest that dioxin-like compounds influence thyroid function, although human studies have presented equivocal results. Great Lakes sportfish consumers represent a population with greater potential for exposure to dioxin-like compounds than non-consumers. Thirty-eight licensed anglers participating in a...

Cite
Bloom M, Vena J, Olson J, et al. Chronic exposure to dioxin-like compounds and thyroid function among New York anglers. Environ Toxicol Pharmacol. 2005;21(3):260-7doi: 10.1016/j.etap.2005.09.001.
Bloom, M., Vena, J., Olson, J., & Moysich, K. (2006). Chronic exposure to dioxin-like compounds and thyroid function among New York anglers. Environmental toxicology and pharmacology, 21(3), 260-7. https://doi.org/10.1016/j.etap.2005.09.001
Bloom, Michael, et al. "Chronic exposure to dioxin-like compounds and thyroid function among New York anglers." Environmental toxicology and pharmacology vol. 21,3 (2006): 260-7. doi: https://doi.org/10.1016/j.etap.2005.09.001
Bloom M, Vena J, Olson J, Moysich K. Chronic exposure to dioxin-like compounds and thyroid function among New York anglers. Environ Toxicol Pharmacol. 2006 May;21(3):260-7. doi: 10.1016/j.etap.2005.09.001. Epub 2005 Oct 24. PMID: 21783667.
Copy Download .nbib Format: NLM
LIFETIME PHYSICAL INACTIVITY IS ASSOCIATED WITH LUNG CANCER RISK AND MORTALITY.

Cancer treatment and research communications

Cannioto R, Etter JL, LaMonte MJ, Ray AD, Joseph JM, Al Qassim E, Eng KH, Moysich KB.
PMID: 29632898
Cancer Treat Res Commun. 2018;14:37-45. doi: 10.1016/j.ctarc.2018.01.001.

DISCUSSION/CONCLUSION: These data add to the body of evidence suggesting that physical inactivity is an independent risk and prognostic factor for cancer. Additional research utilizing prospectively collected data is needed to substantiate the current findings.

Cite
Cannioto R, Etter JL, LaMonte MJ, et al. LIFETIME PHYSICAL INACTIVITY IS ASSOCIATED WITH LUNG CANCER RISK AND MORTALITY. Cancer Treat Res Commun. 2018;14:37-45doi: 10.1016/j.ctarc.2018.01.001.
Cannioto, R., Etter, J. L., LaMonte, M. J., Ray, A. D., Joseph, J. M., Al Qassim, E., Eng, K. H., & Moysich, K. B. (2018). LIFETIME PHYSICAL INACTIVITY IS ASSOCIATED WITH LUNG CANCER RISK AND MORTALITY. Cancer treatment and research communications, 1437-45. https://doi.org/10.1016/j.ctarc.2018.01.001
Cannioto, Rikki, et al. "LIFETIME PHYSICAL INACTIVITY IS ASSOCIATED WITH LUNG CANCER RISK AND MORTALITY." Cancer treatment and research communications vol. 14 (2018): 37-45. doi: https://doi.org/10.1016/j.ctarc.2018.01.001
Cannioto R, Etter JL, LaMonte MJ, Ray AD, Joseph JM, Al Qassim E, Eng KH, Moysich KB. LIFETIME PHYSICAL INACTIVITY IS ASSOCIATED WITH LUNG CANCER RISK AND MORTALITY. Cancer Treat Res Commun. 2018;14:37-45. doi: 10.1016/j.ctarc.2018.01.001. PMID: 29632898; PMCID: PMC5889080.
Copy Download .nbib Format: NLM
Validated biomarker assays confirm ARID1A loss is confounded with MMR deficiency, CD8 TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas.

The Journal of pathology

Heinze K, Nazeran TM, Lee S, Krämer P, Cairns ES, Chiu DS, Leung SCY, Kang EY, Meagher NS, Kennedy CJ, Boros J, Kommoss F, Vollert HW, Heitze F, du Bois A, Harter P, Grube M, Kraemer B, Staebler A, Kommoss FKF, Heublein S, Sinn HP, Singh N, Laslavic A, Elishaev E, Olawaiye A, Moysich K, Modugno F, Sharma R, Brand AH, Harnett PR, DeFazio A, Fortner RT, Lubinski J, Lener M, Tołoczko-Grabarek A, Cybulski C, Gronwald H, Gronwald J, Coulson P, El-Bahrawy MA, Jones ME, Schoemaker MJ, Swerdlow AJ, Gorringe KL, Campbell I, Cook L, Gayther SA, Carney ME, Shvetsov YB, Hernandez BY, Wilkens LR, Goodman MT, Mateoiu C, Linder A, Sundfeldt K, Kelemen LE, Gentry-Maharaj A, Widschwendter M, Menon U, Bolton KL, Alsop J, Shah M, Jimenez-Linan M, Pharoah PDP, Brenton JD, Cushing-Haugen KL, Harris HR, Doherty JA, Gilks B, Ghatage P, Huntsman DG, Nelson GS, Tinker AV, Lee CH, Goode EL, Nelson BH, Ramus SJ, Kommoss S, Talhouk A, Köbel M, Anglesio MS.
PMID: 34897700
J Pathol. 2021 Dec 13; doi: 10.1002/path.5849. Epub 2021 Dec 13.

ARID1A (BAF250a) is a component of the SWI/SNF chromatin modifying complex, plays an important tumour suppressor role, and is considered prognostic in several malignancies. However, in ovarian carcinomas there are contradictory reports on its relationship to outcome, immune response,...

Cite
Heinze K, Nazeran TM, Lee S, et al. Validated biomarker assays confirm ARID1A loss is confounded with MMR deficiency, CD8 TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas. J Pathol. 2021;doi: 10.1002/path.5849.
Heinze, K., Nazeran, T. M., Lee, S., Krämer, P., Cairns, E. S., Chiu, D. S., Leung, S. C. Y., Kang, E. Y., Meagher, N. S., Kennedy, C. J., Boros, J., Kommoss, F., Vollert, H. W., Heitze, F., du Bois, A., Harter, P., Grube, M., Kraemer, B., Staebler, A., Kommoss, F. K. F., Heublein, S., Sinn, H. P., Singh, N., Laslavic, A., Elishaev, E., Olawaiye, A., Moysich, K., Modugno, F., Sharma, R., Brand, A. H., Harnett, P. R., DeFazio, A., Fortner, R. T., Lubinski, J., Lener, M., Tołoczko-Grabarek, A., Cybulski, C., Gronwald, H., Gronwald, J., Coulson, P., El-Bahrawy, M. A., Jones, M. E., Schoemaker, M. J., Swerdlow, A. J., Gorringe, K. L., Campbell, I., Cook, L., Gayther, S. A., Carney, M. E., Shvetsov, Y. B., Hernandez, B. Y., Wilkens, L. R., Goodman, M. T., Mateoiu, C., Linder, A., Sundfeldt, K., Kelemen, L. E., Gentry-Maharaj, A., Widschwendter, M., Menon, U., Bolton, K. L., Alsop, J., Shah, M., Jimenez-Linan, M., Pharoah, P. D. P., Brenton, J. D., Cushing-Haugen, K. L., Harris, H. R., Doherty, J. A., Gilks, B., Ghatage, P., Huntsman, D. G., Nelson, G. S., Tinker, A. V., Lee, C. H., Goode, E. L., Nelson, B. H., Ramus, S. J., Kommoss, S., Talhouk, A., Köbel, M., & Anglesio, M. S. (2021). Validated biomarker assays confirm ARID1A loss is confounded with MMR deficiency, CD8 TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas. The Journal of pathology, . https://doi.org/10.1002/path.5849
Heinze, Karolin, et al. "Validated biomarker assays confirm ARID1A loss is confounded with MMR deficiency, CD8 TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas." The Journal of pathology vol. (2021). doi: https://doi.org/10.1002/path.5849
Heinze K, Nazeran TM, Lee S, Krämer P, Cairns ES, Chiu DS, Leung SCY, Kang EY, Meagher NS, Kennedy CJ, Boros J, Kommoss F, Vollert HW, Heitze F, du Bois A, Harter P, Grube M, Kraemer B, Staebler A, Kommoss FKF, Heublein S, Sinn HP, Singh N, Laslavic A, Elishaev E, Olawaiye A, Moysich K, Modugno F, Sharma R, Brand AH, Harnett PR, DeFazio A, Fortner RT, Lubinski J, Lener M, Tołoczko-Grabarek A, Cybulski C, Gronwald H, Gronwald J, Coulson P, El-Bahrawy MA, Jones ME, Schoemaker MJ, Swerdlow AJ, Gorringe KL, Campbell I, Cook L, Gayther SA, Carney ME, Shvetsov YB, Hernandez BY, Wilkens LR, Goodman MT, Mateoiu C, Linder A, Sundfeldt K, Kelemen LE, Gentry-Maharaj A, Widschwendter M, Menon U, Bolton KL, Alsop J, Shah M, Jimenez-Linan M, Pharoah PDP, Brenton JD, Cushing-Haugen KL, Harris HR, Doherty JA, Gilks B, Ghatage P, Huntsman DG, Nelson GS, Tinker AV, Lee CH, Goode EL, Nelson BH, Ramus SJ, Kommoss S, Talhouk A, Köbel M, Anglesio MS. Validated biomarker assays confirm ARID1A loss is confounded with MMR deficiency, CD8 TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas. J Pathol. 2021 Dec 13; doi: 10.1002/path.5849. Epub 2021 Dec 13. PMID: 34897700.
Copy Download .nbib Format: NLM
Depot-Medroxyprogesterone Acetate Use Is Associated with Decreased Risk of Ovarian Cancer: The Mounting Evidence of a Protective Role of Progestins.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

Phung MT, Lee AW, Wu AH, Berchuck A, Cho KR, Cramer DW, Doherty JA, Goodman MT, Hanley GE, Harris HR, McLean K, Modugno F, Moysich KB, Mukherjee B, Schildkraut JM, Terry KL, Titus LJ, Jordan SJ, Webb PM, Pike MC, Pearce CL.
PMID: 33619020
Cancer Epidemiol Biomarkers Prev. 2021 May;30(5):927-935. doi: 10.1158/1055-9965.EPI-20-1355. Epub 2021 Feb 22.

BACKGROUND: Combined oral contraceptive use is associated with a decreased risk of invasive epithelial ovarian cancer (ovarian cancer). There is suggestive evidence of an inverse association between progestin-only contraceptive use and ovarian cancer risk, but previous studies have been...

Cite
Phung MT, Lee AW, Wu AH, et al. Depot-Medroxyprogesterone Acetate Use Is Associated with Decreased Risk of Ovarian Cancer: The Mounting Evidence of a Protective Role of Progestins. Cancer Epidemiol Biomarkers Prev. 2021;30(5):927-935doi: 10.1158/1055-9965.EPI-20-1355.
Phung, M. T., Lee, A. W., Wu, A. H., Berchuck, A., Cho, K. R., Cramer, D. W., Doherty, J. A., Goodman, M. T., Hanley, G. E., Harris, H. R., McLean, K., Modugno, F., Moysich, K. B., Mukherjee, B., Schildkraut, J. M., Terry, K. L., Titus, L. J., Jordan, S. J., Webb, P. M., Pike, M. C., Pearce, C. L. (2021). Depot-Medroxyprogesterone Acetate Use Is Associated with Decreased Risk of Ovarian Cancer: The Mounting Evidence of a Protective Role of Progestins. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 30(5), 927-935. https://doi.org/10.1158/1055-9965.EPI-20-1355
Phung, Minh Tung, et al. "Depot-Medroxyprogesterone Acetate Use Is Associated with Decreased Risk of Ovarian Cancer: The Mounting Evidence of a Protective Role of Progestins." Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology vol. 30,5 (2021): 927-935. doi: https://doi.org/10.1158/1055-9965.EPI-20-1355
Phung MT, Lee AW, Wu AH, Berchuck A, Cho KR, Cramer DW, Doherty JA, Goodman MT, Hanley GE, Harris HR, McLean K, Modugno F, Moysich KB, Mukherjee B, Schildkraut JM, Terry KL, Titus LJ, Jordan SJ, Webb PM, Pike MC, Pearce CL. Depot-Medroxyprogesterone Acetate Use Is Associated with Decreased Risk of Ovarian Cancer: The Mounting Evidence of a Protective Role of Progestins. Cancer Epidemiol Biomarkers Prev. 2021 May;30(5):927-935. doi: 10.1158/1055-9965.EPI-20-1355. Epub 2021 Feb 22. PMID: 33619020.
Copy Download .nbib Format: NLM
Transmission of X-linked Ovarian Cancer: Characterization and Implications.

Diagnostics (Basel, Switzerland)

Etter JL, Moysich K, Kohli S, Lele S, Odunsi K, Eng KH.
PMID: 32046210
Diagnostics (Basel). 2020 Feb 07;10(2). doi: 10.3390/diagnostics10020090.

We recently reported evidence that a strong, BRCA-independent locus on the X-chromosome may contribute to ovarian cancer predisposition in families ascertained from the Familial Ovarian Cancer Registry (Buffalo, NY, USA). While it has been estimated that approximately 20% of...

Cite
Etter JL, Moysich K, Kohli S, et al. Transmission of X-linked Ovarian Cancer: Characterization and Implications. Diagnostics (Basel). 2020;10(2)doi: 10.3390/diagnostics10020090.
Etter, J. L., Moysich, K., Kohli, S., Lele, S., Odunsi, K., & Eng, K. H. (2020). Transmission of X-linked Ovarian Cancer: Characterization and Implications. Diagnostics (Basel, Switzerland), 10(2), . https://doi.org/10.3390/diagnostics10020090
Etter, John Lewis, et al. "Transmission of X-linked Ovarian Cancer: Characterization and Implications." Diagnostics (Basel, Switzerland) vol. 10,2 (2020). doi: https://doi.org/10.3390/diagnostics10020090
Etter JL, Moysich K, Kohli S, Lele S, Odunsi K, Eng KH. Transmission of X-linked Ovarian Cancer: Characterization and Implications. Diagnostics (Basel). 2020 Feb 07;10(2). doi: 10.3390/diagnostics10020090. PMID: 32046210; PMCID: PMC7167857.
Copy Download .nbib Format: NLM
Assessment of the Prognostic Value of Two Common Variants of BRCA1 and BRCA2 Genes in Ovarian Cancer Patients Treated with Cisplatin and Paclitaxel: A Gynecologic Oncology Group Study.

Frontiers in oncology

Tian CQ, Darcy KM, Krivak TC, Deloia JA, Armstrong D, Davis W, Zhao H, Moysich K, Ambrosone CB.
PMID: 23964347
Front Oncol. 2013 Aug 12;3:206. doi: 10.3389/fonc.2013.00206. eCollection 2013.

PURPOSE: BRCA1/BRCA2 germline mutations appear to enhance the platinum-sensitivity, but little is known about the prognostic relevance of polymorphisms in BRCA1/BRCA2 in epithelial ovarian cancer (EOC). This study evaluated whether common variants of BRCA1/BRCA2 are associated with progression-free survival...

Cite
Tian CQ, Darcy KM, Krivak TC, et al. Assessment of the Prognostic Value of Two Common Variants of BRCA1 and BRCA2 Genes in Ovarian Cancer Patients Treated with Cisplatin and Paclitaxel: A Gynecologic Oncology Group Study. Front Oncol. 2013;3:206doi: 10.3389/fonc.2013.00206.
Tian, C. Q., Darcy, K. M., Krivak, T. C., Deloia, J. A., Armstrong, D., Davis, W., Zhao, H., Moysich, K., & Ambrosone, C. B. (2013). Assessment of the Prognostic Value of Two Common Variants of BRCA1 and BRCA2 Genes in Ovarian Cancer Patients Treated with Cisplatin and Paclitaxel: A Gynecologic Oncology Group Study. Frontiers in oncology, 3206. https://doi.org/10.3389/fonc.2013.00206
Tian, Chunqiao Q, et al. "Assessment of the Prognostic Value of Two Common Variants of BRCA1 and BRCA2 Genes in Ovarian Cancer Patients Treated with Cisplatin and Paclitaxel: A Gynecologic Oncology Group Study." Frontiers in oncology vol. 3 (2013): 206. doi: https://doi.org/10.3389/fonc.2013.00206
Tian CQ, Darcy KM, Krivak TC, Deloia JA, Armstrong D, Davis W, Zhao H, Moysich K, Ambrosone CB. Assessment of the Prognostic Value of Two Common Variants of BRCA1 and BRCA2 Genes in Ovarian Cancer Patients Treated with Cisplatin and Paclitaxel: A Gynecologic Oncology Group Study. Front Oncol. 2013 Aug 12;3:206. doi: 10.3389/fonc.2013.00206. eCollection 2013. PMID: 23964347; PMCID: PMC3740480.
Copy Download .nbib Format: NLM
Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC).

Journal of genetics and genome research

Jim HS, Lin HY, Tyrer JP, Lawrenson K, Dennis J, Chornokur G, Chen Z, Chen AY, Permuth-Wey J, Aben KK, Anton-Culver H, Antonenkova N, Bruinsma F, Bandera EV, Bean YT, Beckmann MW, Bisogna M, Bjorge L, Bogdanova N, Brinton LA, Brooks-Wilson A, Bunker CH, Butzow R, Campbell IG, Carty K, Chang-Claude J, Cook LS, Cramer DW, Cunningham JM, Cybulski C, Dansonka-Mieszkowska A, du Bois A, Despierre E, Sieh W, Doherty JA, Dörk T, Dürst M, Easton DF, Eccles DM, Edwards RP, Ekici AB, Fasching PA, Fridley BL, Gao YT, Gentry-Maharaj A, Giles GG, Glasspool R, Goodman MT, Gronwald J, Harter P, Hasmad HN, Hein A, Heitz F, Hildebrandt MA, Hillemanns P, Hogdall CK, Hogdall E, Hosono S, Iversen ES, Jakubowska A, Jensen A, Ji BT, Karlan BY, Kellar M, Kiemeney LA, Krakstad C, Kjaer SK, Kupryjanczyk J, Vierkant RA, Lambrechts D, Lambrechts S, Le ND, Lee AW, Lele S, Leminen A, Lester J, Levine DA, Liang D, Lim BK, Lissowska J, Lu K, Lubinski J, Lundvall L, Massuger LF, Matsuo K, McGuire V, McLaughlin JR, McNeish I, Menon U, Milne RL, Modugno F, Thomsen L, Moysich KB, Ness RB, Nevanlinna H, Eilber U, Odunsi K, Olson SH, Orlow I, Orsulic S, Palmieri Weber R, Paul J, Pearce CL, Pejovic T, Pelttari LM, Pike MC, Poole EM, Schernhammer E, Risch HA, Rosen B, Rossing MA, Rothstein JH, Rudolph A, Runnebaum IB, Rzepecka IK, Salvesen HB, Schwaab I, Shu XO, Shvetsov YB, Siddiqui N, Song H, Southey MC, Spiewankiewicz B, Sucheston-Campbell L, Teo SH, Terry KL, Thompson PJ, Tangen IL, Tworoger SS, van Altena AM, Vergote I, Walsh CS, Wang-Gohrke S, Wentzensen N, Whittemore AS, Wicklund KG, Wilkens LR, Wu AH, Wu X, Woo YL, Yang H, Zheng W, Ziogas A, Amankwah E, Berchuck A, Schildkraut JM, Kelemen LE, Ramus SJ, Monteiro AN, Goode EL, Narod SA, Gayther SA, Pharoah PD, Sellers TA, Phelan CM.
PMID: 26807442
J Genet Genome Res. 2015;2(2). doi: 10.23937/2378-3648/1410017. Epub 2015 Sep 15.

Disruption in circadian gene expression, whether due to genetic variation or environmental factors (e.g., light at night, shiftwork), is associated with increased incidence of breast, prostate, gastrointestinal and hematologic cancers and gliomas. Circadian genes are highly expressed in the...

Cite
Jim HS, Lin HY, Tyrer JP, et al. Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC). J Genet Genome Res. 2015;2(2)doi: 10.23937/2378-3648/1410017.
Jim, H. S., Lin, H. Y., Tyrer, J. P., Lawrenson, K., Dennis, J., Chornokur, G., Chen, Z., Chen, A. Y., Permuth-Wey, J., Aben, K. K., Anton-Culver, H., Antonenkova, N., Bruinsma, F., Bandera, E. V., Bean, Y. T., Beckmann, M. W., Bisogna, M., Bjorge, L., Bogdanova, N., Brinton, L. A., Brooks-Wilson, A., Bunker, C. H., Butzow, R., Campbell, I. G., Carty, K., Chang-Claude, J., Cook, L. S., Cramer, D. W., Cunningham, J. M., Cybulski, C., Dansonka-Mieszkowska, A., du Bois, A., Despierre, E., Sieh, W., Doherty, J. A., Dörk, T., Dürst, M., Easton, D. F., Eccles, D. M., Edwards, R. P., Ekici, A. B., Fasching, P. A., Fridley, B. L., Gao, Y. T., Gentry-Maharaj, A., Giles, G. G., Glasspool, R., Goodman, M. T., Gronwald, J., Harter, P., Hasmad, H. N., Hein, A., Heitz, F., Hildebrandt, M. A., Hillemanns, P., Hogdall, C. K., Hogdall, E., Hosono, S., Iversen, E. S., Jakubowska, A., Jensen, A., Ji, B. T., Karlan, B. Y., Kellar, M., Kiemeney, L. A., Krakstad, C., Kjaer, S. K., Kupryjanczyk, J., Vierkant, R. A., Lambrechts, D., Lambrechts, S., Le, N. D., Lee, A. W., Lele, S., Leminen, A., Lester, J., Levine, D. A., Liang, D., Lim, B. K., Lissowska, J., Lu, K., Lubinski, J., Lundvall, L., Massuger, L. F., Matsuo, K., McGuire, V., McLaughlin, J. R., McNeish, I., Menon, U., Milne, R. L., Modugno, F., Thomsen, L., Moysich, K. B., Ness, R. B., Nevanlinna, H., Eilber, U., Odunsi, K., Olson, S. H., Orlow, I., Orsulic, S., Palmieri Weber, R., Paul, J., Pearce, C. L., Pejovic, T., Pelttari, L. M., Pike, M. C., Poole, E. M., Schernhammer, E., Risch, H. A., Rosen, B., Rossing, M. A., Rothstein, J. H., Rudolph, A., Runnebaum, I. B., Rzepecka, I. K., Salvesen, H. B., Schwaab, I., Shu, X. O., Shvetsov, Y. B., Siddiqui, N., Song, H., Southey, M. C., Spiewankiewicz, B., Sucheston-Campbell, L., Teo, S. H., Terry, K. L., Thompson, P. J., Tangen, I. L., Tworoger, S. S., van Altena, A. M., Vergote, I., Walsh, C. S., Wang-Gohrke, S., Wentzensen, N., Whittemore, A. S., Wicklund, K. G., Wilkens, L. R., Wu, A. H., Wu, X., Woo, Y. L., Yang, H., Zheng, W., Ziogas, A., Amankwah, E., Berchuck, A., Schildkraut, J. M., Kelemen, L. E., Ramus, S. J., Monteiro, A. N., Goode, E. L., Narod, S. A., Gayther, S. A., Pharoah, P. D., Sellers, T. A., & Phelan, C. M. (2015). Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC). Journal of genetics and genome research, 2(2), . https://doi.org/10.23937/2378-3648/1410017
Jim, Heather S L, et al. "Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC)." Journal of genetics and genome research vol. 2,2 (2015). doi: https://doi.org/10.23937/2378-3648/1410017
Jim HS, Lin HY, Tyrer JP, Lawrenson K, Dennis J, Chornokur G, Chen Z, Chen AY, Permuth-Wey J, Aben KK, Anton-Culver H, Antonenkova N, Bruinsma F, Bandera EV, Bean YT, Beckmann MW, Bisogna M, Bjorge L, Bogdanova N, Brinton LA, Brooks-Wilson A, Bunker CH, Butzow R, Campbell IG, Carty K, Chang-Claude J, Cook LS, Cramer DW, Cunningham JM, Cybulski C, Dansonka-Mieszkowska A, du Bois A, Despierre E, Sieh W, Doherty JA, Dörk T, Dürst M, Easton DF, Eccles DM, Edwards RP, Ekici AB, Fasching PA, Fridley BL, Gao YT, Gentry-Maharaj A, Giles GG, Glasspool R, Goodman MT, Gronwald J, Harter P, Hasmad HN, Hein A, Heitz F, Hildebrandt MA, Hillemanns P, Hogdall CK, Hogdall E, Hosono S, Iversen ES, Jakubowska A, Jensen A, Ji BT, Karlan BY, Kellar M, Kiemeney LA, Krakstad C, Kjaer SK, Kupryjanczyk J, Vierkant RA, Lambrechts D, Lambrechts S, Le ND, Lee AW, Lele S, Leminen A, Lester J, Levine DA, Liang D, Lim BK, Lissowska J, Lu K, Lubinski J, Lundvall L, Massuger LF, Matsuo K, McGuire V, McLaughlin JR, McNeish I, Menon U, Milne RL, Modugno F, Thomsen L, Moysich KB, Ness RB, Nevanlinna H, Eilber U, Odunsi K, Olson SH, Orlow I, Orsulic S, Palmieri Weber R, Paul J, Pearce CL, Pejovic T, Pelttari LM, Pike MC, Poole EM, Schernhammer E, Risch HA, Rosen B, Rossing MA, Rothstein JH, Rudolph A, Runnebaum IB, Rzepecka IK, Salvesen HB, Schwaab I, Shu XO, Shvetsov YB, Siddiqui N, Song H, Southey MC, Spiewankiewicz B, Sucheston-Campbell L, Teo SH, Terry KL, Thompson PJ, Tangen IL, Tworoger SS, van Altena AM, Vergote I, Walsh CS, Wang-Gohrke S, Wentzensen N, Whittemore AS, Wicklund KG, Wilkens LR, Wu AH, Wu X, Woo YL, Yang H, Zheng W, Ziogas A, Amankwah E, Berchuck A, Schildkraut JM, Kelemen LE, Ramus SJ, Monteiro AN, Goode EL, Narod SA, Gayther SA, Pharoah PD, Sellers TA, Phelan CM. Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC). J Genet Genome Res. 2015;2(2). doi: 10.23937/2378-3648/1410017. Epub 2015 Sep 15. PMID: 26807442; PMCID: PMC4722961.
Copy Download .nbib Format: NLM
Corrigendum: Common variants at 19p13 are associated with susceptibility to ovarian cancer.

Nature genetics

Bolton KL, Tyrer J, Song H, Ramus SJ, Notaridou M, Jones C, Sher T, Gentry-Maharaj A, Wozniak E, Tsai YY, Weidhaas J, Paik D, Van Den Berg DJ, Stram DO, Pearce CL, Wu AH, Brewster W, Anton-Culver H, Ziogas A, Narod SA, Levine DA, Kaye SB, Brown R, Paul J, Flanagan J, Sieh W, McGuire V, Whittemore AS, Campbell I, Gore ME, Lissowska J, Yang HP, Medrek K, Gronwald J, Lubinski J, Jakubowska A, Le ND, Cook LS, Kelemen LE, Brooks-Wilson A, Massuger LF, Kiemeney LA, Aben KK, van Altena AM, Houlston R, Tomlinson I, Palmieri RT, Moorman PG, Schildkraut J, Iversen ES, Phelan C, Vierkant RA, Cunningham JM, Goode EL, Fridley BL, Kruger-Kjaer S, Blaeker J, Hogdall E, Hogdall C, Gross J, Karlan BY, Ness RB, Edwards RP, Odunsi K, Moyisch KB, Baker JA, Modugno F, Heikkinenen T, Butzow R, Nevanlinna H, Leminen A, Bogdanova N, Antonenkova N, Doerk T, Hillemanns P, Dürst M, Runnebaum I, Thompson PJ, Carney ME, Goodman MT, Lurie G, Wang-Gohrke S, Hein R, Chang-Claude J, Rossing MA, Cushing-Haugen KL, Doherty J, Chen C, Rafnar T, Besenbacher S, Sulem P, Stefansson K, Birrer MJ, Terry KL, Hernandez D, Cramer DW, Vergote I, Amant F, Lambrechts D, Despierre E, Fasching PA, Beckmann MW, Thiel FC, Ekici AB, Chen X, Johnatty SE, Webb PM, Beesley J, Chanock S, Garcia-Closas M, Sellers T, Easton DF, Berchuck A, Chenevix-Trench G, Pharoah PD, Gayther SA.
PMID: 26711112
Nat Genet. 2016 Jan;48(1):101. doi: 10.1038/ng0116-101b.

No abstract available.

Cite
Bolton KL, Tyrer J, Song H, et al. Corrigendum: Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet. 2016;48(1):101doi: 10.1038/ng0116-101b.
Bolton, K. L., Tyrer, J., Song, H., Ramus, S. J., Notaridou, M., Jones, C., Sher, T., Gentry-Maharaj, A., Wozniak, E., Tsai, Y. Y., Weidhaas, J., Paik, D., Van Den Berg, D. J., Stram, D. O., Pearce, C. L., Wu, A. H., Brewster, W., Anton-Culver, H., Ziogas, A., Narod, S. A., Levine, D. A., Kaye, S. B., Brown, R., Paul, J., Flanagan, J., Sieh, W., McGuire, V., Whittemore, A. S., Campbell, I., Gore, M. E., Lissowska, J., Yang, H. P., Medrek, K., Gronwald, J., Lubinski, J., Jakubowska, A., Le, N. D., Cook, L. S., Kelemen, L. E., Brooks-Wilson, A., Massuger, L. F., Kiemeney, L. A., Aben, K. K., van Altena, A. M., Houlston, R., Tomlinson, I., Palmieri, R. T., Moorman, P. G., Schildkraut, J., Iversen, E. S., Phelan, C., Vierkant, R. A., Cunningham, J. M., Goode, E. L., Fridley, B. L., Kruger-Kjaer, S., Blaeker, J., Hogdall, E., Hogdall, C., Gross, J., Karlan, B. Y., Ness, R. B., Edwards, R. P., Odunsi, K., Moyisch, K. B., Baker, J. A., Modugno, F., Heikkinenen, T., Butzow, R., Nevanlinna, H., Leminen, A., Bogdanova, N., Antonenkova, N., Doerk, T., Hillemanns, P., Dürst, M., Runnebaum, I., Thompson, P. J., Carney, M. E., Goodman, M. T., Lurie, G., Wang-Gohrke, S., Hein, R., Chang-Claude, J., Rossing, M. A., Cushing-Haugen, K. L., Doherty, J., Chen, C., Rafnar, T., Besenbacher, S., Sulem, P., Stefansson, K., Birrer, M. J., Terry, K. L., Hernandez, D., Cramer, D. W., Vergote, I., Amant, F., Lambrechts, D., Despierre, E., Fasching, P. A., Beckmann, M. W., Thiel, F. C., Ekici, A. B., Chen, X., Johnatty, S. E., Webb, P. M., Beesley, J., Chanock, S., Garcia-Closas, M., Sellers, T., Easton, D. F., Berchuck, A., Chenevix-Trench, G., Pharoah, P. D., & Gayther, S. A. (2016). Corrigendum: Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nature genetics, 48(1), 101. https://doi.org/10.1038/ng0116-101b
Bolton, Kelly L, et al. "Corrigendum: Common variants at 19p13 are associated with susceptibility to ovarian cancer." Nature genetics vol. 48,1 (2016): 101. doi: https://doi.org/10.1038/ng0116-101b
Bolton KL, Tyrer J, Song H, Ramus SJ, Notaridou M, Jones C, Sher T, Gentry-Maharaj A, Wozniak E, Tsai YY, Weidhaas J, Paik D, Van Den Berg DJ, Stram DO, Pearce CL, Wu AH, Brewster W, Anton-Culver H, Ziogas A, Narod SA, Levine DA, Kaye SB, Brown R, Paul J, Flanagan J, Sieh W, McGuire V, Whittemore AS, Campbell I, Gore ME, Lissowska J, Yang HP, Medrek K, Gronwald J, Lubinski J, Jakubowska A, Le ND, Cook LS, Kelemen LE, Brooks-Wilson A, Massuger LF, Kiemeney LA, Aben KK, van Altena AM, Houlston R, Tomlinson I, Palmieri RT, Moorman PG, Schildkraut J, Iversen ES, Phelan C, Vierkant RA, Cunningham JM, Goode EL, Fridley BL, Kruger-Kjaer S, Blaeker J, Hogdall E, Hogdall C, Gross J, Karlan BY, Ness RB, Edwards RP, Odunsi K, Moyisch KB, Baker JA, Modugno F, Heikkinenen T, Butzow R, Nevanlinna H, Leminen A, Bogdanova N, Antonenkova N, Doerk T, Hillemanns P, Dürst M, Runnebaum I, Thompson PJ, Carney ME, Goodman MT, Lurie G, Wang-Gohrke S, Hein R, Chang-Claude J, Rossing MA, Cushing-Haugen KL, Doherty J, Chen C, Rafnar T, Besenbacher S, Sulem P, Stefansson K, Birrer MJ, Terry KL, Hernandez D, Cramer DW, Vergote I, Amant F, Lambrechts D, Despierre E, Fasching PA, Beckmann MW, Thiel FC, Ekici AB, Chen X, Johnatty SE, Webb PM, Beesley J, Chanock S, Garcia-Closas M, Sellers T, Easton DF, Berchuck A, Chenevix-Trench G, Pharoah PD, Gayther SA. Corrigendum: Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet. 2016 Jan;48(1):101. doi: 10.1038/ng0116-101b. PMID: 26711112.
Copy Download .nbib Format: NLM
Endometriosis and menopausal hormone therapy impact the hysterectomy-ovarian cancer association.

Gynecologic oncology

Khoja L, Weber RP, Webb PM, Jordan SJ, Muthukumar A, Chang-Claude J, Fortner RT, Jensen A, Kjaer SK, Risch H, Doherty JA, Harris HR, Goodman MT, Modugno F, Moysich K, Berchuck A, Schildkraut JM, Cramer D, Terry KL, Anton-Culver H, Ziogas A, Phung MT, Hanley GE, Wu AH, Mukherjee B, McLean K, Cho K, Pike MC, Pearce CL, Lee AW.
PMID: 34776242
Gynecol Oncol. 2022 Jan;164(1):195-201. doi: 10.1016/j.ygyno.2021.10.088. Epub 2021 Nov 12.

OBJECTIVE: To evaluate the association between hysterectomy and ovarian cancer, and to understand how hormone therapy (HT) use and endometriosis affect this association.METHODS: We conducted a pooled analysis of self-reported data from 11 case-control studies in the Ovarian Cancer...

Cite
Khoja L, Weber RP, et al. Endometriosis and menopausal hormone therapy impact the hysterectomy-ovarian cancer association. Gynecol Oncol. 2021;164(1):195-201doi: 10.1016/j.ygyno.2021.10.088.
Khoja, L., Weber, R. P., Webb, P. M., Jordan, S. J., Muthukumar, A., Chang-Claude, J., Fortner, R. T., Jensen, A., Kjaer, S. K., Risch, H., Doherty, J. A., Harris, H. R., Goodman, M. T., Modugno, F., Moysich, K., Berchuck, A., Schildkraut, J. M., Cramer, D., Terry, K. L., Anton-Culver, H., Ziogas, A., Phung, M. T., Hanley, G. E., Wu, A. H., Mukherjee, B., McLean, K., Cho, K., Pike, M. C., Pearce, C. L., & Lee, A. W. (2022). Endometriosis and menopausal hormone therapy impact the hysterectomy-ovarian cancer association. Gynecologic oncology, 164(1), 195-201. https://doi.org/10.1016/j.ygyno.2021.10.088
Khoja, Lilah, et al. "Endometriosis and menopausal hormone therapy impact the hysterectomy-ovarian cancer association." Gynecologic oncology vol. 164,1 (2022): 195-201. doi: https://doi.org/10.1016/j.ygyno.2021.10.088
Khoja L, Weber RP, Webb PM, Jordan SJ, Muthukumar A, Chang-Claude J, Fortner RT, Jensen A, Kjaer SK, Risch H, Doherty JA, Harris HR, Goodman MT, Modugno F, Moysich K, Berchuck A, Schildkraut JM, Cramer D, Terry KL, Anton-Culver H, Ziogas A, Phung MT, Hanley GE, Wu AH, Mukherjee B, McLean K, Cho K, Pike MC, Pearce CL, Lee AW. Endometriosis and menopausal hormone therapy impact the hysterectomy-ovarian cancer association. Gynecol Oncol. 2022 Jan;164(1):195-201. doi: 10.1016/j.ygyno.2021.10.088. Epub 2021 Nov 12. PMID: 34776242.
Copy Download .nbib Format: NLM
Clinical and Lifestyle-Related Prognostic Indicators among Esophageal Adenocarcinoma Patients Receiving Treatment at a Comprehensive Cancer Center.

Cancers

Dighe SG, Yan L, Mukherjee S, McGillicuddy CS, Hulme KL, Hochwald SN, Yendamuri S, Bain AJ, Robillard KT, Moysich KB, Ambrosone CB, Millen AE, Buas MF.
PMID: 34572881
Cancers (Basel). 2021 Sep 16;13(18). doi: 10.3390/cancers13184653.

PURPOSE: The incidence of esophageal adenocarcinoma (EAC) has risen substantially in recent decades, while the average 5-year survival remains only ~20%. Disease stage and treatment are the strongest prognostic factors. The role of lifestyle factors in relation to survival...

Cite
Dighe SG, Yan L, Mukherjee S, et al. Clinical and Lifestyle-Related Prognostic Indicators among Esophageal Adenocarcinoma Patients Receiving Treatment at a Comprehensive Cancer Center. Cancers (Basel). 2021;13(18)doi: 10.3390/cancers13184653.
Dighe, S. G., Yan, L., Mukherjee, S., McGillicuddy, C. S., Hulme, K. L., Hochwald, S. N., Yendamuri, S., Bain, A. J., Robillard, K. T., Moysich, K. B., Ambrosone, C. B., Millen, A. E., & Buas, M. F. (2021). Clinical and Lifestyle-Related Prognostic Indicators among Esophageal Adenocarcinoma Patients Receiving Treatment at a Comprehensive Cancer Center. Cancers, 13(18), . https://doi.org/10.3390/cancers13184653
Dighe, Shruti G, et al. "Clinical and Lifestyle-Related Prognostic Indicators among Esophageal Adenocarcinoma Patients Receiving Treatment at a Comprehensive Cancer Center." Cancers vol. 13,18 (2021). doi: https://doi.org/10.3390/cancers13184653
Dighe SG, Yan L, Mukherjee S, McGillicuddy CS, Hulme KL, Hochwald SN, Yendamuri S, Bain AJ, Robillard KT, Moysich KB, Ambrosone CB, Millen AE, Buas MF. Clinical and Lifestyle-Related Prognostic Indicators among Esophageal Adenocarcinoma Patients Receiving Treatment at a Comprehensive Cancer Center. Cancers (Basel). 2021 Sep 16;13(18). doi: 10.3390/cancers13184653. PMID: 34572881; PMCID: PMC8465866.
Copy Download .nbib Format: NLM
High Prediagnosis Inflammation-Related Risk Score Associated with Decreased Ovarian Cancer Survival.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

Brieger KK, Phung MT, Mukherjee B, Bakulski KM, Anton-Culver H, Bandera EV, Bowtell DDL, Cramer DW, DeFazio A, Doherty JA, Fereday S, Fortner RT, Gentry-Maharaj A, Goode EL, Goodman MT, Harris HR, Matsuo K, Menon U, Modugno F, Moysich KB, Qin B, Ramus SJ, Risch HA, Rossing MA, Schildkraut JM, Trabert B, Vierkant RA, Winham SJ, Wentzensen N, Wu AH, Ziogas A, Khoja L, Cho KR, McLean K, Richardson J, Grout B, Chase A, Deurloo CM, Odunsi K, Nelson BH, Brenton JD, Terry KL, Pharoah PDP, Berchuck A, Hanley GE, Webb PM, Pike MC, Pearce CL.
PMID: 34789471
Cancer Epidemiol Biomarkers Prev. 2021 Nov 17; doi: 10.1158/1055-9965.EPI-21-0977. Epub 2021 Nov 17.

BACKGROUND: There is suggestive evidence that inflammation is related to ovarian cancer survival. However, more research is needed to identify inflammation-related factors that are associated with ovarian cancer survival and to determine their combined effects.METHODS: This analysis used pooled...

Cite
Brieger KK, Phung MT, Mukherjee B, et al. High Prediagnosis Inflammation-Related Risk Score Associated with Decreased Ovarian Cancer Survival. Cancer Epidemiol Biomarkers Prev. 2021;doi: 10.1158/1055-9965.EPI-21-0977.
Brieger, K. K., Phung, M. T., Mukherjee, B., Bakulski, K. M., Anton-Culver, H., Bandera, E. V., Bowtell, D. D. L., Cramer, D. W., DeFazio, A., Doherty, J. A., Fereday, S., Fortner, R. T., Gentry-Maharaj, A., Goode, E. L., Goodman, M. T., Harris, H. R., Matsuo, K., Menon, U., Modugno, F., Moysich, K. B., Qin, B., Ramus, S. J., Risch, H. A., Rossing, M. A., Schildkraut, J. M., Trabert, B., Vierkant, R. A., Winham, S. J., Wentzensen, N., Wu, A. H., Ziogas, A., Khoja, L., Cho, K. R., McLean, K., Richardson, J., Grout, B., Chase, A., Deurloo, C. M., Odunsi, K., Nelson, B. H., Brenton, J. D., Terry, K. L., Pharoah, P. D. P., Berchuck, A., Hanley, G. E., Webb, P. M., Pike, M. C., Pearce, C. L. (2021). High Prediagnosis Inflammation-Related Risk Score Associated with Decreased Ovarian Cancer Survival. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, . https://doi.org/10.1158/1055-9965.EPI-21-0977
Brieger, Katharine K, et al. "High Prediagnosis Inflammation-Related Risk Score Associated with Decreased Ovarian Cancer Survival." Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology vol. (2021). doi: https://doi.org/10.1158/1055-9965.EPI-21-0977
Brieger KK, Phung MT, Mukherjee B, Bakulski KM, Anton-Culver H, Bandera EV, Bowtell DDL, Cramer DW, DeFazio A, Doherty JA, Fereday S, Fortner RT, Gentry-Maharaj A, Goode EL, Goodman MT, Harris HR, Matsuo K, Menon U, Modugno F, Moysich KB, Qin B, Ramus SJ, Risch HA, Rossing MA, Schildkraut JM, Trabert B, Vierkant RA, Winham SJ, Wentzensen N, Wu AH, Ziogas A, Khoja L, Cho KR, McLean K, Richardson J, Grout B, Chase A, Deurloo CM, Odunsi K, Nelson BH, Brenton JD, Terry KL, Pharoah PDP, Berchuck A, Hanley GE, Webb PM, Pike MC, Pearce CL. High Prediagnosis Inflammation-Related Risk Score Associated with Decreased Ovarian Cancer Survival. Cancer Epidemiol Biomarkers Prev. 2021 Nov 17; doi: 10.1158/1055-9965.EPI-21-0977. Epub 2021 Nov 17. PMID: 34789471.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 37 entries